Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T18:00:31.163Z.
Calculation as of: 2026-10-06T18:00:31.163Z.
Quote observation: 2026-10-06T18:00:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 06927155e4c2426002f4bce692deae0e66dfd07f15f24b5879cea6ac7a363957
PEG RATIO
N/A
Market Cap
$3.79B
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.41B
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $4.05B | N/A | N/A | N/A | N/A |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.00B | N/A | N/A | N/A | N/A |
| ICU Medical, Inc. (ICUI)vs › | $3.96B | N/A | 25.16 | 11.69 | 23.54 |
| LivaNova PLC (LIVN)vs › | $4.15B | N/A | 1.95 | 1.95 | 1.95 |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.28B | N/A | N/A | N/A | N/A |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.79B | N/A | N/A | N/A | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.41B | N/A | N/A | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.41B | N/A | 0.39 | 0.39 | 0.39 |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.44B | N/A | N/A | N/A | N/A |
| Veracyte, Inc. (VCYT)vs › | $3.55B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
